Deregulation of the spindle assembly checkpoint is associated with paclitaxel resistance in ovarian cancer

Journal of Ovarian Research

Linda Liao¹  Nicola Lyttle¹  John M. S. Bartlett¹  Melanie Spears¹  Amila Sarac¹  Taryne Chong¹  Paul C. Boutros²  Cindy Q. Yao² 

[1] Diagnostic Development, Ontario Institute for Cancer Research, MaRS Centre;Informatics Program, Ontario Institute for Cancer Research, MaRS Centre;

关键词: Spindle assembly checkpoint;    Ovarian cancer;    Paclitaxel;    Mitotic checkpoint serine/threonine kinase (BUB1);    centromere protein E (CENPE);    Centromere protein F (CENPF);   

DOI  :  10.1186/s13048-018-0399-7

来源: DOAJ

【 摘 要 】

Abstract Background Ovarian cancer is the leading gynecologic cancer diagnosed in North America and because related symptoms are not disease specific, this often leads to late detection, an advanced disease state, and the need for chemotherapy. Ovarian cancer is frequently sensitive to chemotherapy at diagnosis but rapid development of drug resistance leads to disease progression and ultimately death in the majority of patients. Results We have generated paclitaxel resistant ovarian cell lines from their corresponding native cell lines to determine driver mechanisms of drug resistance using gene expression arrays. These paclitaxel resistant ovarian cells demonstrate: (1) Increased IC50 for paclitaxel and docetaxel (10 to 75-fold) and cross-resistance to anthracyclines (2) Reduced cell apoptosis in the presence of paclitaxel (3) Gene depletion involving mitotic regulators BUB1 mitotic checkpoint serine/threonine kinase, cyclin BI (CCNB1), centromere protein E (CENPE), and centromere protein F (CENPF), and (4) Functional data validating gene depletion among mitotic regulators. Conclusions We have generated model systems to explore drug resistance in ovarian cancer, which have revealed a key pathway related to the spindle assembly checkpoint underlying paclitaxel resistance in ovarian cell lines.

【 授权许可】

Unknown